NZ734041A - Crystalline forms of c21h22cl2n4o2 - Google Patents
Crystalline forms of c21h22cl2n4o2Info
- Publication number
- NZ734041A NZ734041A NZ734041A NZ73404116A NZ734041A NZ 734041 A NZ734041 A NZ 734041A NZ 734041 A NZ734041 A NZ 734041A NZ 73404116 A NZ73404116 A NZ 73404116A NZ 734041 A NZ734041 A NZ 734041A
- Authority
- NZ
- New Zealand
- Prior art keywords
- crystalline forms
- isopropylaminopyridin
- pyrrole
- chlorophenyl
- chloro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Developing Agents For Electrophotography (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Removal Of Specific Substances (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ772411A NZ772411A (en) | 2015-01-30 | 2016-01-29 | Crystalline forms of c21h22ci2n4o2 |
| NZ783866A NZ783866B2 (en) | 2016-01-29 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | |
| NZ783808A NZ783808B2 (en) | 2016-01-29 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562110449P | 2015-01-30 | 2015-01-30 | |
| PCT/US2016/015829 WO2016123574A1 (en) | 2015-01-30 | 2016-01-29 | Crystalline forms of c21h22ci2n4o2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ734041A true NZ734041A (en) | 2022-02-25 |
Family
ID=56544441
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ734041A NZ734041A (en) | 2015-01-30 | 2016-01-29 | Crystalline forms of c21h22cl2n4o2 |
| NZ772411A NZ772411A (en) | 2015-01-30 | 2016-01-29 | Crystalline forms of c21h22ci2n4o2 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ772411A NZ772411A (en) | 2015-01-30 | 2016-01-29 | Crystalline forms of c21h22ci2n4o2 |
Country Status (12)
| Country | Link |
|---|---|
| US (6) | US9676746B2 (enExample) |
| EP (2) | EP3250562B1 (enExample) |
| JP (5) | JP7258460B2 (enExample) |
| CN (2) | CN116854662A (enExample) |
| AU (5) | AU2016211246B2 (enExample) |
| CA (3) | CA3218488A1 (enExample) |
| ES (1) | ES3009552T3 (enExample) |
| HK (1) | HK1244274A1 (enExample) |
| MX (1) | MX382289B (enExample) |
| NZ (2) | NZ734041A (enExample) |
| SG (2) | SG11201705924RA (enExample) |
| WO (1) | WO2016123574A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015095842A2 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers |
| SG11201705924RA (en) | 2015-01-30 | 2017-08-30 | Biomed Valley Discoveries Inc | CRYSTALLINE FORMS OF C<sb>21</sb>H<sb>22</sb>CI<sb>2</sb>N<sb>4</sb>O<sb>2</sb> |
| MX380123B (es) * | 2016-01-27 | 2025-03-11 | Jiangsu Hengrui Medicine Co | Metodo para preparar una composicion farmaceutica que comprende un derivado de quinolina o una sal del mismo. |
| US10172862B2 (en) * | 2017-01-30 | 2019-01-08 | Oncoceutics, Inc. | Imipridones for gliomas |
| WO2021020841A1 (en) * | 2019-07-29 | 2021-02-04 | Standigm Inc. | Composition for preventing or treating metabolic liver disease |
| US20230024584A1 (en) * | 2019-11-20 | 2023-01-26 | University Of Kentucky Research Foundation | Anti-cancer compositions and methods |
| CN118765276A (zh) * | 2022-03-08 | 2024-10-11 | 甘李药业股份有限公司 | 氘代化合物，及其制备方法和应用 |
| WO2023183905A2 (en) * | 2022-03-24 | 2023-09-28 | Biomed Valley Discoveries, Inc. | Deuterated analogs of pyrrole inhibitors of erk, synthesis thereof and intermediates thereto |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4599331A (en) | 1984-12-24 | 1986-07-08 | Syntex (U.S.A.) Inc. | Etianic acids as antiangiogenics |
| EP0245357B1 (en) | 1985-10-23 | 1991-08-07 | The Upjohn Company | Angiostatic steroids |
| US4771042A (en) | 1985-11-25 | 1988-09-13 | The Upjohn Company | Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments |
| EP0477195A1 (en) | 1989-06-16 | 1992-04-01 | The Upjohn Company | Suramin type compounds and angiostatic steroids to inhibit angiogenesis |
| AU678961B2 (en) | 1991-11-22 | 1997-06-19 | Alcon Laboratories, Inc. | Angiostatic steroids |
| JP4783532B2 (ja) * | 2000-02-05 | 2011-09-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｅｒｋのインヒビターとして有用なピラゾール組成物 |
| US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| EP1506189A1 (en) * | 2002-04-26 | 2005-02-16 | Vertex Pharmaceuticals Incorporated | Pyrrole derivatives as inhibitors of erk2 and uses thereof |
| ES2897422T3 (es) * | 2004-05-14 | 2022-03-01 | Vertex Pharma | Compuestos pirroles como inhibidores de proteínas cinasas ERK y composiciones farmacéuticas que contienen esos compuestos |
| US7582623B2 (en) | 2004-05-20 | 2009-09-01 | The Regents Of The University Of California | Photoactive metal nitrosyls for blood pressure regulation and cancer therapy |
| CN103951583B (zh) | 2006-12-06 | 2016-01-06 | 科内图斯医药公司 | 一种抑制剂的结晶形式 |
| JP6362601B2 (ja) * | 2012-09-18 | 2018-07-25 | オースペックス・ファーマシューティカルズ・インコーポレイテッドＡｕｓｐｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 小胞モノアミン輸送体２の重水素化ベンゾキノリン阻害剤の製剤薬物動態 |
| US9227969B2 (en) * | 2013-08-14 | 2016-01-05 | Novartis Ag | Compounds and compositions as inhibitors of MEK |
| SG11201705924RA (en) | 2015-01-30 | 2017-08-30 | Biomed Valley Discoveries Inc | CRYSTALLINE FORMS OF C<sb>21</sb>H<sb>22</sb>CI<sb>2</sb>N<sb>4</sb>O<sb>2</sb> |
-
2016
- 2016-01-29 SG SG11201705924RA patent/SG11201705924RA/en unknown
- 2016-01-29 JP JP2017539596A patent/JP7258460B2/ja active Active
- 2016-01-29 EP EP16744240.9A patent/EP3250562B1/en active Active
- 2016-01-29 EP EP24203987.3A patent/EP4477222A3/en active Pending
- 2016-01-29 MX MX2017009696A patent/MX382289B/es unknown
- 2016-01-29 CN CN202310821608.XA patent/CN116854662A/zh active Pending
- 2016-01-29 WO PCT/US2016/015829 patent/WO2016123574A1/en not_active Ceased
- 2016-01-29 ES ES16744240T patent/ES3009552T3/es active Active
- 2016-01-29 SG SG10202101979TA patent/SG10202101979TA/en unknown
- 2016-01-29 NZ NZ734041A patent/NZ734041A/en unknown
- 2016-01-29 CA CA3218488A patent/CA3218488A1/en active Pending
- 2016-01-29 NZ NZ772411A patent/NZ772411A/en unknown
- 2016-01-29 US US15/011,377 patent/US9676746B2/en active Active
- 2016-01-29 HK HK18103713.0A patent/HK1244274A1/zh unknown
- 2016-01-29 AU AU2016211246A patent/AU2016211246B2/en active Active
- 2016-01-29 CA CA2975048A patent/CA2975048C/en active Active
- 2016-01-29 CA CA3308777A patent/CA3308777A1/en active Pending
- 2016-01-29 CN CN201680013774.5A patent/CN107406413A/zh active Pending
-
2017
- 2017-05-17 US US15/598,181 patent/US10183927B2/en active Active
-
2018
- 2018-12-20 US US16/227,820 patent/US10738027B2/en active Active
-
2020
- 2020-03-31 JP JP2020063198A patent/JP2020100674A/ja active Pending
- 2020-07-07 US US16/922,365 patent/US11390600B2/en active Active
- 2020-10-20 AU AU2020257041A patent/AU2020257041C1/en active Active
-
2021
- 2021-12-01 JP JP2021195403A patent/JP2022033866A/ja active Pending
-
2022
- 2022-06-16 US US17/842,632 patent/US12187698B2/en active Active
- 2022-09-05 AU AU2022228084A patent/AU2022228084B2/en active Active
-
2023
- 2023-05-17 JP JP2023081553A patent/JP2023096080A/ja not_active Withdrawn
- 2023-10-25 AU AU2023254937A patent/AU2023254937B2/en active Active
-
2024
- 2024-11-26 US US18/960,604 patent/US20250084059A1/en active Pending
-
2025
- 2025-03-25 JP JP2025050047A patent/JP2025089464A/ja active Pending
- 2025-11-10 AU AU2025263912A patent/AU2025263912A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX382289B (es) | Formas cristalinas de c21h22cl2n4o2. | |
| MX2016015005A (es) | Derivados de pirrolidina-2,5-diona, composiciones farmaceuticas y metodos para usar como inhibidores ido1. | |
| MX389597B (es) | Inhibidores de cdk2/4/6 de piridopirimidinona. | |
| WO2015200481A8 (en) | Mnk inhibitors and methods related thereto | |
| PH12016502378A1 (en) | Substituted dihydroisoquinolinone compounds | |
| PH12018500610B1 (en) | Isoindolinone inhibitors of the mdm2-p53 interaction having anticancer activity | |
| MX2015012431A (es) | Pirrol amida como inhibidores. | |
| MX2013012776A (es) | Inhibidores de la tirosina cinasa de bazo que contienen aminopiridina. | |
| MX2014012695A (es) | Derivados de isoindolona. | |
| WO2014031438A3 (en) | SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS | |
| HK1206021A1 (en) | Novel ring-substituted n-pyridinyl amides as kinase inhibitors | |
| GEP20186892B (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease | |
| PH12018500626A1 (en) | Isoindolinone inhibitors of the mdm2-p53 interaction having anticancer activity | |
| PH12017500089A1 (en) | Aldosterone synthase inhibitors | |
| PH12017500595B1 (en) | Aldosterone synthase inhibitors | |
| TN2017000342A1 (en) | Novel cyclopropabenzofuranyl pyridopyrazinediones | |
| MX2017008076A (es) | DERIVADOS DE IMIDAZOPIRIDAZINA ENLAZADOS A HETEROCICLILO COMO INHIBIDORES DE PI3Kß. | |
| PH12016502281A1 (en) | Pyrrolidine-2,5-dione derivatives, pharmaceutical compositions and methods for use as ido1 inhibitors | |
| MA39993A (fr) | Dérivés de pyrrolidine -2,5-dione, compositions pharmaceutiques et procédés pour une utilisation en tant qu'inhibiteursde de ido1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 JAN 2024 BY CPA GLOBAL Effective date: 20221216 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 JAN 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20240201 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 JAN 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20241212 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 JAN 2027 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20251218 |